15 25

Cited 0 times in

Cited 0 times in

International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI)

Authors
 V. Radke, Nishant  ;  Van Dijk, Elon H. C.  ;  Spaide, Richard F.  ;  Holz, Frank G.  ;  Koizumi, Hideki  ;  Freund, K. Bailey  ;  Subhi, Yousif  ;  Lange, Clemens  ;  Singh, Sumit Randhir  ;  Chen, Li Jia  ;  Chen, San-Ni  ;  Chhablani, Jay  ;  Behar-Cohen, Francine  ;  Das, Taraprasad  ;  Fung, Adrian T.  ;  Gomi, Fumi  ;  Kim, Min  ;  Chen, Haoyu  ;  Lai, Chi-Chun  ;  Lai, Timothy Y. Y.  ;  Lee, Christopher Seungkyu  ;  Lotery, Andrew  ;  Sivaprasad, Sobha  ;  Zhao, Mingwei  ;  Lam, Dennis S. C.  ;  Boon, Camiel J. F. 
Citation
 ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, Vol.14(5), 2025-09 
Article Number
 100252 
Journal Title
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
ISSN
 2162-0989 
Issue Date
2025-09
Keywords
Controversies ; Consensuses ; Guidelines ; APVRS ; AAPPO ; ARI ; Central Serous Chorioretinopathy
Abstract
Purpose: To establish consensus-based guidelines on the diagnosis, classification, and management of central serous chorioretinopathy (CSC) through a structured expert panel initiated by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), and the Academia Retina Internationalis (ARI), addressing the existing clinical controversies. Methods: An international panel of 26 experts from 13 countries collaboratively drafted consensus statements spanning five key areas: disease definition, pathophysiology, investigations, current management, and future developments. Consensus was reached through an iterative Delphi process and anonymous voting using a five-point Likert scale. Statements were accepted when >75 % agreement ('agree' & 'strongly agree') was achieved. Results: Consensus was achieved for all 25 statements, reflecting strong alignment among experts. Key agreements included defining CSC as a pachychoroid-driven chorioretinal disorder characterized by neurosensory retinal and/or RPE detachment, with multimodal imaging (optical coherence tomography, fundus auto-fluorescence, fluorescein angiography, and indocyanine green angiography) recognized as essential for diagnosis. Half-dose photodynamic therapy (PDT) was unanimously endorsed as the first-line treatment for chronic CSC. Oral mineralocorticoid receptor antagonists (MRAs) lacked consensus for therapeutic benefit, aligning with evidence from the VICI and SPECTRA trials. Anti-vascular endothelial growth factor receptor therapy was recommended solely for CSC complicated by a macular neovascularization. Future priorities highlighted standardizing disease classification and exploring targeted therapies through genetic and nanomedicine research. Conclusion: This consensus initiative provides a robust, evidence-based framework for the diagnosis and management of CSC, promoting standardization across clinical practices and guiding future research directions to address persistent gaps in CSC care.
Files in This Item:
90396.pdf Download
DOI
10.1016/j.apjo.2025.100252
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Christopher Seungkyu(이승규) ORCID logo https://orcid.org/0000-0001-5054-9470
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/209702
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links